Boston Scientific (BSX)
(Delayed Data from NYSE)
$83.92 USD
+0.21 (0.25%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $83.93 +0.01 (0.01%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth A Momentum B VGM
Price, Consensus and EPS Surprise
BSX 83.92 +0.21(0.25%)
Will BSX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for BSX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BSX
Is Boston Scientific (BSX) a Solid Growth Stock? 3 Reasons to Think "Yes"
Boston Scientific (BSX) Is Up 2.10% in One Week: What You Should Know
BSX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Think Boston Scientific (BSX) Is a Good Investment: Is It?
Boston Scientific Corporation (BSX) Soars to 52-Week High, Time to Cash Out?
Innovation Aids Alcon Stock's Growth Despite Macroeconomic Troubles
Other News for BSX
Janus Henderson Global Life Sciences Fund Q2 2024 Commentary
Janus Henderson Enterprise Fund Q2 2024 Commentary
Boston Scientific: Forward Returns Are Likely To Be Disappointing For Investors
BSX May 2025 Options Begin Trading
Orbimed Advisors LLC Reduces Stake in Passage Bio Inc